Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...
Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand ...
The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boehringer Ingelheim's (BI) diabetes alliance, following litigation filed by Sanofi ...
oGrowing insulin demand in rural and underserved regions, expanding market penetration. Get Your Free Sample Market Report: What Are the Future Growth Projections for the Basaglar Market?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback